TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02162329

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalography (EEG)
Description: Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalography (EEG)
Description: Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (fMRI
Description: Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit.
Study: NCT02508077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study: NCT01130376

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GTU-MultiHIV B clade vaccine1mg
Description: Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-MultiHIV B clade vaccine1mg
Description: Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: 5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
Study: NCT02162329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (fMRI
Description: Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit.
Study: NCT01130376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: 150 ug administered subcutaneously once daily 4 hours from IL-2 injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 150 ug administered subcutaneously once daily 4 hours from IL-2 injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: 4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: 4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
Study: NCT04471857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Study: NCT04806711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menicon Z Night
Description: Menicon Z Night orthokeratology contact lenses were used to assess their efficacy in reducing myopia progression in children

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Distance, single-vision glasses were used as a control
Study: NCT03136640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study: NCT00957320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
Study: NCT03896035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention Group
Description: The behavioral intervention is designed for older Veterans with cLBP and depression and will include 8 individual telephone sessions delivered by health coaches over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
Study: NCT00687037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride
Study: NCT03902379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive CCI intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01183676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEPAKOTE® Tablets, 500 MG
Description: 1 x 500 mg Tablet, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
Description: 1 x 500 mg Tablet, under fed conditions
Study: NCT00957476

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fish Oil
Description: 800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Fish Oil
Description: 800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
Study: NCT02162329

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (fMRI
Description: Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Classes
Description: Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
Study: NCT04385810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmologic exam
Description: Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital
Study: NCT03455179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow-speed traditional resistance training
Description: The training session will consist in a general warm-up, 6 resistance exercises, including 2 upper limb exercises (elbow curl and chest press), 2 lower limb exercises (lunge and standing hip abduction), and 2 exercises combining both upper and lower limbs at the same time (squat plus upright rowing and squat plus shoulder press) and finally the cooldown routine.The participants will perform in each training session 6 submaximal repetitions equivalent to 85% of the one-repetition maximum (1RM) and 3-4 sets per exercise (high intensity training sessions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed resistance training
Description: The participants will perform the same exercises than the TRADICIONAL group with12 submaximal repetitions equivalent to 40-50% 1RM (low-intensity) and 3-4 sets per exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training
Description: Participants will perform, in this order, balance exercises followed by resistance/coordination, aerobic/coordination and flexibility exercises in each session. The balance training will consist in static, dynamic and proactive balance exercises. In the resistance training block, the participants will perform 3-4 sets of 15 submaximal repetitions Participants will perform 2 resistance exercises (squat plus upright rowing and lunge) at traditional slow-speed (2s of concentric contraction and 2s of eccentric contraction).The intensity of the aerobic block will progress from 65 to 85% of the maximum heart rate over the training weeks.
Study: NCT01939600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch-free breakfast
Description: Starch-free breakfast alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hi-Maize 260
Description: Starch-free breakfast plus 55.3g Hi-Maize 260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hylon VII
Description: Starch-free breakfast plus 56.9g Hylon VII
Study: NCT00957320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
Study: NCT02185326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone (Norditropin, Novo nordisk)
Description: Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
Study: NCT03554733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReInventing Yourself after SCI
Description: 6-week, manualized, cognitive-behaviorally based group educational intervention
Study: NCT04267679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: 25 mg full-spectrum CBD soft gel capsules
Study: NCT00478816

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad H5N1 Pandemic Influenza Vaccine
Description: Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad H5N1 Pandemic Influenza Vaccine
Description: Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.
Study: NCT04386655

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Injur Coping Skills - Telemedicine
Description: BICS sessions (both in-person and telemedicine) will occur once a week for 12 weeks. Each session will last two hours.~Modules of BICS include: Introduction to Brain Injury, Expectations for Recovery, Tips on Managing Challenging Problems, Learning about Depression after the Brain Injury, The 4 R's of Stress Management, Communicating Effectively with Professionals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Injur Coping Skills - Telemedicine
Description: BICS sessions (both in-person and telemedicine) will occur once a week for 12 weeks. Each session will last two hours.~Modules of BICS include: Introduction to Brain Injury, Expectations for Recovery, Tips on Managing Challenging Problems, Learning about Depression after the Brain Injury, The 4 R's of Stress Management, Communicating Effectively with Professionals
Study: NCT02888041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocine
Description: In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
Study: NCT02920008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guadecitabine
Description: In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m\^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Choice (TC)
Description: * High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).~* Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.~* Best Supportive Care (BSC).
Study: NCT03325634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT04454866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single injection of penehyclidine
Description: A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of penehyclidine
Description: A dose of penehyclidine hydrochloride (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine hydrochloride (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Study: NCT03668119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT04454866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Study: NCT01320046

Intervention type: OTHER
Intervention: Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage
Description: Patients will undergo the following evaluation:~1. Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~2. Medical history.~3. Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~4. Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~5. Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours.

Intervention type: OTHER
Intervention: Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage
Description: Patients will undergo the following evaluation:~1. Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~2. Medical history.~3. Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~4. Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~5. Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours.
Study: NCT01692340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotopically labeled lycopene, phytoene or phytofluene
Description: We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotopically labeled lycopene, phytoene or phytofluene
Description: We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotopically labeled lycopene, phytoene or phytofluene
Description: We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
Study: NCT00517712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single agent arsenic trioxide
Description: duration of maintenance therapy, 6 months versus 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single agent arsenic trioxide
Description: duration of maintenance therapy, 6 months versus 12 months
Study: NCT02478619

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IMT group
Description: Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.~They will also receive the routine physical therapy in the post operative period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
Study: NCT01386528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
Study: NCT05888636

Intervention type: OTHER
Intervention: ChIP-seq, NGS, ATAC-seq
Description: Bone narrow sampling

Intervention type: OTHER
Intervention: ChIP-seq, NGS, ATAC-seq
Description: Bone narrow sampling

Intervention type: OTHER
Intervention: ChIP-seq, NGS, ATAC-seq
Description: Bone narrow sampling
Study: NCT00951483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine-XR
Description: Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
Study: NCT04973865

Intervention type: OTHER
Intervention: Validation & reliability
Description: Translated version of IPAQ(SF) validation \& Reliability

Intervention type: OTHER
Intervention: Validation & reliability
Description: Translated version of IPAQ(SF) validation \& Reliability
Study: NCT00562887

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every 4 weeks, IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: 400 mg IV every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: 700 mg IV every 4 weeks
Study: NCT02014714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.